Back HIV/AIDS HIV/AIDS Topics HIV Treatment

CROI 2017: New HIV Infections Fall in the U.S. but Disparities Remain

The number of annual new HIV infections in the U.S. fell by 18% overall since 2008, offering evidence that prevention and treatment efforts are having an impact, according to data from the Centers for Disease Control and Prevention (CDC) released to coincidence with presentations at the 2017 Conference on Retroviruses and Opportunistic Infections this week in Seattle. A closer look at the data, however, shows some notable differences across demographic groups and geographic regions.

alt

Read more:

CROI 2017: Integrase Inhibitor Bictegravir Matches Dolutegravir for First-Line HIV Treatment

Bictegravir, an investigational integrase inhibitor from Gilead Sciences, was highly potent, well tolerated and worked as well as dolutegravir (Tivcay) in a Phase 2 clinical trial, according to study results presented at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) this week in Seattle and published online in The Lancet HIV.

alt

Read more:

Top 10 HIV and Hepatitis Stories of 2016

Simplification and optimization of antiretroviral therapy for HIV, wider use of pre-exposure prophylaxis (PrEP), a growing appreciation that people with undetectable viral load do not transmit HIV, and an expanded armamentarium of treatments for hepatitis C were among the top HIV and viral hepatitis headlines this year. Here's a look back at some of our biggest news from 2016.

alt

Read more:

CROI 2017: Dual Antiretroviral Regimen Maintains Durable HIV Suppression after Switch

People who switched from standard antiretroviral therapy to a 2-drug regimen of dolutegravir (Tivicay) plus rilpivirine (Edurant) were able to maintain an undetectable viral load for 48 weeks in a pair of late-stage clinical trials, according to a late-breaking report at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) this week in Seattle.

alt

Read more:

Dolutegravir + Rilpivirine HIV Maintenance Regimen Looks Good in Phase 3 Studies

Switching to a 2-drug regimen of dolutegravir plus rilpivirine maintained viral suppression among people on successful 3- or 4-drug antiretroviral therapy (ART) in a pair of Phase 3 clinical trials, according to an announcement last week from ViiV Healthcare.

alt

Read more:

HIVandHepatitis.com 2016 Conference Coverage

Article listings by topic for HIVandHepatitis.com conference coverage in 2016, including the Conference on Retroviruses and Opportunistic Infections, EASL International Liver Congress, International AIDS Conference, and AASLD Liver Meeting.

alt

Read more:

2. Quicker, Simpler, and Better Antiretroviral Therapy

Modern antiretroviral therapy (ART) is highly effective and well-tolerated, but researchers continue to refine, streamline, and optimize treatment strategies. Studies presented this year show the benefits of starting ART as soon as possible after HIV diagnosis and suggest that fewer drugs taken less often may be effective for many people.

alt

Read more: